A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
by on Friday, June 1st, 2012 | No Comments
Condition: Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: interferon alfa-2a [Roferon-A]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed – verified May 2012
See the original post: A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma